GSK vets theorize that a mitochondrial target may unlock Parkinson's and ALS treatments in new startup
Can targeting a mitochondrial pathway previously thought to be undruggable crack the code in devastating neurodegenerative diseases, such as Parkinson’s and ALS? For a new British startup, that’s the £16 million question.
NRG Therapeutics unveiled its Series A early Wednesday morning on the backs of two GSK vets and their research that, they claim, has pinpointed a way to protect mitochondria from the hallmark neuronal damage seen in neurodegeneration. If everything goes according to plan, the biotech could develop “disease-modifying” small molecule treatments for both Parkinson’s and ALS, CEO Neil Miller told Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.